Correspondence 0001193125-23-097786 from AN2 Therapeutics, Inc. (ANTX)
AN2 Therapeutics, Inc.
Date: April 11, 2023 · CIK: 0001880438 · Accession: 0001193125-23-097786
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-271174
Letter
Re: AN2 Therapeutics, Inc.
April 11, 2023
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attn: Jason Drory
Registration Statement on Form S-3
File No. 333-271174
Acceleration Request
Requested Date: April 13, 2023
Requested Time: 4:00 PM Eastern Daylight Time
Ladies and Gentlemen:
In accordance with Rule 461 under the Securities Act of 1933, as amended, the undersigned registrant (the “Registrant”) hereby requests that the U.S. Securities and Exchange Commission (the “Commission”) take appropriate action to cause the Registration Statement on Form S-3 (File No. 333-271174) (the “Registration Statement”) to become effective on April 13, 2023 at 4:00 p.m. Eastern Daylight Time, or as soon as practicable thereafter, or at such later time as the Registrant may orally request via telephone call to the staff of the Commission (the “Staff”). The Registrant hereby authorizes Josh Seidenfeld of Cooley LLP, or, in his absence, Sally Kay of Cooley LLP, counsel to the Registrant, to make such request on its behalf.
Once the Registration Statement has been declared effective, please orally confirm that event with Josh Seidenfeld of Cooley LLP, counsel to the Registrant, at (650) 843-5862, or, in his absence, Sally Kay of Cooley LLP, counsel to the Registrant at (650) 843-5582.
Very truly yours,
AN2 Therapeutics, Inc.
Show Raw Text
CORRESP 1 filename1.htm CORRESP April 11, 2023 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Jason Drory Re: AN2 Therapeutics, Inc. Registration Statement on Form S-3 File No. 333-271174 Acceleration Request Requested Date: April 13, 2023 Requested Time: 4:00 PM Eastern Daylight Time Ladies and Gentlemen: In accordance with Rule 461 under the Securities Act of 1933, as amended, the undersigned registrant (the “Registrant”) hereby requests that the U.S. Securities and Exchange Commission (the “Commission”) take appropriate action to cause the Registration Statement on Form S-3 (File No. 333-271174) (the “Registration Statement”) to become effective on April 13, 2023 at 4:00 p.m. Eastern Daylight Time, or as soon as practicable thereafter, or at such later time as the Registrant may orally request via telephone call to the staff of the Commission (the “Staff”). The Registrant hereby authorizes Josh Seidenfeld of Cooley LLP, or, in his absence, Sally Kay of Cooley LLP, counsel to the Registrant, to make such request on its behalf. Once the Registration Statement has been declared effective, please orally confirm that event with Josh Seidenfeld of Cooley LLP, counsel to the Registrant, at (650) 843-5862, or, in his absence, Sally Kay of Cooley LLP, counsel to the Registrant at (650) 843-5582. Very truly yours, AN2 Therapeutics, Inc. By: /s/ Eric Easom Eric Easom Chief Executive Officer cc: Josh Seidenfeld, Cooley LLP Sally Kay, Cooley LLP Anitha Anne, Cooley LLP